Short answer
ROCKET PHARMACEUTICALS, INC. (RCKT) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 with net income of $123M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- Net income
- $123M
- +278.8% YoY · +358.9% QoQ
- EPS (diluted)
- $1.08
- +274.2% YoY · +357.1% QoQ
Source: XBRL data from the ROCKET PHARMACEUTICALS, INC. (RCKT) Q2 2026 10-Q on SEC EDGAR. USD.
ROCKET PHARMACEUTICALS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin percentages disclosed
- Best-performing program: RP-A501, with $180M PRV monetization and Phase 2 dosing resumed
- Cash deployment: $180M non-dilutive proceeds from completed PRV sale
- Near-term outlook: Danon regulatory-pathway update expected in second half of 2026; launch preparations continue for KRESLADI™
Risk Factors
- No risk factors provided in the submitted excerpt
- Excerpt begins with Item 2 and contains no Item 1A Risk Factors disclosure
- Priority Review Voucher asset purchase agreement dated April 26, 2026 disclosed as a new exhibit
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ROCKET PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.